Sinatra Raymond S, Jahr Jonathan S, Reynolds Lowell W, Viscusi Eugene R, Groudine Scott B, Payen-Champenois Catherine
Department of Anesthesiology, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520, USA.
Anesthesiology. 2005 Apr;102(4):822-31. doi: 10.1097/00000542-200504000-00019.
Intravenous acetaminophen injection (paracetamol) is marketed in Europe for the management of acute pain. A repeated-dose, randomized, double-blind, placebo-controlled, three-parallel group study was performed to evaluate the analgesic efficacy and safety of intravenous acetaminophen as compared with its prodrug (propacetamol) and placebo. Propacetamol has been available in many European countries for more than 20 yr.
After orthopedic surgery, patients reporting moderate to severe pain received either 1 g intravenous acetaminophen, 2 g propacetamol, or placebo at 6-h intervals over 24 h. Patients were allowed "rescue" intravenous patient-controlled analgesia morphine. Pain intensity, pain relief, and morphine use were measured at selected intervals. Safety was monitored through adverse event reporting, clinical examination, and laboratory testing.
One hundred fifty-one patients (intravenous acetaminophen: 49; propacetamol: 50; placebo: 52) received at least one dose of study medication. The intravenous acetaminophen and propacetamol groups differed significantly from the placebo group regarding pain relief from 15 min to 6 h (P < 0.05) and median time to morphine rescue (intravenous acetaminophen: 3 h; propacetamol: 2.6 h; placebo: 0.8 h). Intravenous acetaminophen and propacetamol significantly reduced morphine consumption over the 24-h period: The total morphine doses received over 24 h were 38.3 +/- 35.1 mg for intravenous acetaminophen, 40.8 +/- 30.2 mg for propacetamol, and 57. 4 +/- 52.3 mg for placebo, corresponding to decreases of -33% (19 mg) and -29% (17 mg) for intravenous acetaminophen and propacetamol, respectively. Drug-related adverse events were reported in 8.2%, 50% (most of them local), and 17.3% of patients treated with intravenous acetaminophen, propacetamol, and placebo, respectively.
Intravenous acetaminophen, 1 g, administered over a 24-h period in patients with moderate to severe pain after orthopedic surgery provided rapid and effective analgesia and was well tolerated.
静脉注射对乙酰氨基酚注射液(扑热息痛)在欧洲上市用于治疗急性疼痛。开展了一项重复给药、随机、双盲、安慰剂对照、三平行组研究,以评估静脉注射对乙酰氨基酚与其前体药物(丙帕他莫)及安慰剂相比的镇痛疗效和安全性。丙帕他莫在许多欧洲国家已上市超过20年。
骨科手术后,报告有中度至重度疼痛的患者在24小时内每隔6小时接受1克静脉注射对乙酰氨基酚、2克丙帕他莫或安慰剂。允许患者使用“补救”静脉自控镇痛吗啡。在选定的时间间隔测量疼痛强度、疼痛缓解情况及吗啡使用量。通过不良事件报告、临床检查和实验室检测监测安全性。
151例患者(静脉注射对乙酰氨基酚组:49例;丙帕他莫组:50例;安慰剂组:52例)接受了至少一剂研究药物。静脉注射对乙酰氨基酚组和丙帕他莫组在15分钟至6小时的疼痛缓解情况(P < 0.05)以及至吗啡补救的中位时间(静脉注射对乙酰氨基酚组:3小时;丙帕他莫组:2.6小时;安慰剂组:0.8小时)方面与安慰剂组有显著差异。静脉注射对乙酰氨基酚和丙帕他莫在24小时内显著减少了吗啡用量:24小时内接受的吗啡总剂量,静脉注射对乙酰氨基酚组为38.3±35.1毫克,丙帕他莫组为40.8±30.2毫克,安慰剂组为57.4±52.3毫克,静脉注射对乙酰氨基酚和丙帕他莫分别减少了-33%(19毫克)和-29%(17毫克)。接受静脉注射对乙酰氨基酚、丙帕他莫和安慰剂治疗的患者中,分别有8.2%、50%(大多数为局部反应)和17.3%报告了与药物相关的不良事件。
骨科手术后中度至重度疼痛患者在24小时内静脉注射1克对乙酰氨基酚可提供快速有效的镇痛,且耐受性良好。